111 completed, 72 unknown, 25 terminated, 20 withdrawn. 233 Phase 3, 61 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 233 | Completed 111, Unknown 72, Terminated 25, Withdrawn 20, Suspended 3, Active not recruiting 2 |
| Phase 2 | 61 | Completed 28, Unknown 20, Terminated 9, Withdrawn 3, Suspended 1 |
Follow Covid19: new trials by email Literature Review of Covid19 trials Research Report on Covid19
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Placebo, Metformin - Covid19 | Phase 3 | Completed | Susanna Naggie, MD | 3214 | 2023-09-05 | 2025-11-18 |
| Early Treatment Strategy With High-dose Dexamethasone in Patients With SARS-CoV-2 Dexamethasone - Covid19, Dexamethasone | Phase 3 | Unknown | Hospital Universitario Infanta Leonor | 200 | 2023-02-28 | 2023-03-01 |
| ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast) Placebo, Montelukast - Covid19 | Phase 3 | Completed | Susanna Naggie, MD | 1453 | 2023-01-27 | 2025-01-17 |
| SARS-CoV-2 and Acetylsalicylic Acid (SARA) Low-dose acetylsalicylic acid, Placebo - SARS-CoV2 Infection, Covid19 | Phase 3 | Completed | Barcelona Institute for Global Health | 38 | 2022-09-14 | 2024-08-15 |
| ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100) Fluvoxamine, Placebo - Covid19 | Phase 3 | Completed | Susanna Naggie, MD | 1208 | 2022-08-25 | 2024-11-15 |
| Efficacy and Safety of Nitazoxanide 600 mg BID Versus Placebo for the Treatment of Hospitalized Patients With COVID-19 Nitazoxanide, Placebo - covid19 | Phase 3 | Unknown | Azidus Brasil | 380 | 2022-06-22 | 2022-10-31 |
| ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600) Ivermectin, Placebo - Covid19 | Phase 3 | Completed | Susanna Naggie, MD | 1459 | 2022-02-16 | 2023-11-03 |
| the Safety and Efficacy of Meplazumab in Patients With COVID-19 Meplazumab for Injection, Sterile normal saline (0.9%) - Covid19 | Phase 2 / Phase 3 | Completed | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | 150 | 2022-01-21 | 2023-09-15 |
| The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients Sitagliptin - Covid19, Diabetes Mellitus, Type 2 | Phase 3 | Unknown | University of Milan | 170 | 2021-12-29 | 2021-09-28 |
| A Study of Baricitinib (LY3009104) in Children With COVID-19 Baricitinib - Covid19, Corona Virus Infection | Phase 3 | Terminated | Eli Lilly and Company | 6 | 2021-12-21 | 2026-08-11 |
| Impact of GSE and Xylitol (Xlear) on COVID-19 Symptoms and Time to PCR Negativisation in COVID-19 Patients GSE and Xylitol, Control Placebo - Covid19 | Phase 3 | Withdrawn | Larkin Community Hospital | 2021-12-16 | 2023-10-16 | |
| Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2 Nasal Spray - Covid19 | Phase 3 | Withdrawn | Larkin Community Hospital | 2021-12-08 | 2023-10-16 | |
| Prophylaxis of COVID-19 Disease With Ivermectin in COVID-19 Contact Persons [German: Prophylaxe Der COVID-19-Erkrankung Mit Ivermectin Bei COVID-19 Kontaktpersonen] Ivermectin, Placebo - Covid19 | Phase 3 | Unknown | Infectopharm Arzneimittel GmbH | 412 | 2021-11-01 | 2021-11-02 |
| Novaferon in Non-hospitalized Adult Patients With Mild COVID-19 Novaferon, Placebo - Covid19 | Phase 3 | Unknown | Genova Inc. | 222 | 2021-10-28 | 2022-03-03 |
| A Phase III Confirmatory Study of K-237 K-237 0.3-0.4mg/kg (once daily), Placebo 0.3-0.4mg/kg (once daily) - Covid19 | Phase 3 | Completed | Kowa Company, Ltd. | 1030 | 2021-10-22 | 2024-05-20 |
| SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial Shampoo and saline, Saline and Listerine, Shampoo and Listerine - Covid19, SARS-CoV Infection | Phase 2 / Phase 3 | Terminated | Milton S. Hershey Medical Center | 171 | 2021-10-01 | 2026-09-14 |
| Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19 Baricitinib, Placebo - Covid19 | Phase 3 | Unknown | Incepta Pharmaceuticals Ltd | 480 | 2021-10-01 | 2021-09-28 |
| A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19 CVnCoV Vaccine - Coronavirus, Covid19 | Phase 3 | Withdrawn | CureVac | 2021-10-01 | 2021-08-20 | |
| A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects GT0918, Standard of care, Matching placebo - Covid19 | Phase 3 | Terminated | Suzhou Kintor Pharmaceutical Inc, | 139 | 2021-09-30 | 2023-08-18 |
| FLuticasone in cOvid Treatment (FLOT) Fluticasone Propionate - Covid19 | Phase 2 / Phase 3 | Unknown | University of Medicine and Pharmacy at Ho Chi Minh City | 500 | 2021-09-22 | 2021-09-23 |
Showing 20 of 233. Sign in to see all of them.
COVID-19 (233) · Severe Acute Respiratory Syndrome (31) · Coronavirus Infections (24) · Virus Diseases (9) · RNA Virus Infections (6) · Coronaviridae Infections (5) · Nidovirales Infections (5) · Respiratory Insufficiency (5) · Pneumonia (4) · Communicable Diseases (3) · Inflammation (3) · Pneumonia, Viral (3) · Thrombosis (3) · Acute Kidney Injury (2) · Critical Illness (2)
Infections (233) · Lung Diseases (233) · Respiratory Tract Diseases (233) · Respiratory Tract Infections (232) · Pneumonia, Viral (230) · Pneumonia (229) · Coronaviridae Infections (228) · Nidovirales Infections (228) · RNA Virus Infections (227) · Virus Diseases (224) · Coronavirus Infections (209) · Pathological Conditions, Signs and Symptoms (20) · Pathologic Processes (16) · Cardiovascular Diseases (7) · Disease Attributes (7)
Standard of Care (19) · Ivermectin (15) · Hydroxychloroquine (12) · remdesivir (11) · Azithromycin (8) · favipiravir (8) · Dexamethasone (6) · Fluvoxamine (6) · tocilizumab (6) · Atorvastatin (5) · Methylprednisolone (5) · CVnCoV COVID-19 vaccine (4) · Cholecalciferol (4) · Heparin (4) · Sodium Chloride (4)
Susanna Naggie, MD (8) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Assistance Publique - Hôpitaux de Paris (4) · Assiut University (4) · CureVac (4) · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (4) · Larkin Community Hospital (4) · University of Sao Paulo (4) · Ain Shams University (3) · Applied Biology, Inc. (3) · Coordinación de Investigación en Salud, Mexico (3) · Genova Inc. (3) · ASST Fatebenefratelli Sacco (2) · Abderrahmane Mami Hospital (2) · Australian National University (2)
United States (48) · Brazil (24) · Egypt (18) · Mexico (17) · Italy (14) · Argentina (13) · Canada (12) · Spain (11) · France (10) · United Kingdom (9) · Bangladesh (6) · Colombia (6) · Denmark (6) · Peru (6) · Philippines (6)
Adrian Hernandez, MD (8) · Susanna Naggie, MD (8) · Prof. James Neaton (4) · Andy Goren, MD (3) · Flavio Cadegiani, MD (3) · Samuel Brown, MD (3) · Akter Kamal, MD, PhD (2) · Frank MP van Haren, MD, PhD (2) · Marcelo Silveira, MD, PhD (2) · Omar Soliman, MD (2) · Zhanghua Lan, PhD (2) · Abdelhakim F Ghallab, MD (1) · Abdelrahman A Abdelalim, MD (1) · Ahmad Imran, MBBS (1)
PMID 34473343, PMID 35244208, PMID 35713300, PMID 37489818, PMID 37591523, PMID 32142651, PMID 32171076, PMID 32187464, PMID 33502773, PMID 35180412, PMID 36695483, PMID 36700518, PMID 11594901, PMID 12480795, PMID 1593279, PMID 15992957, PMID 16103157, PMID 16103202, PMID 18446504, PMID 22417684, PMID 23320022, PMID 23769930, PMID 24161512, PMID 25645191, PMID 25822153, PMID 26491864, PMID 26752081, PMID 26988202, PMID 27550352, PMID 28934952, PMID 30536180, PMID 31023272, PMID 31282542, PMID 31442620, PMID 31722941, PMID 32109013, PMID 32150748, PMID 32202722, PMID 32251768, PMID 32282022, PMID 32293834, PMID 32313880, PMID 32360300, PMID 32407672, PMID 32497319, PMID 32992075, PMID 33065103, PMID 33227231, PMID 33234158, PMID 33356051
U24TR001608 (8), 1OT2HL156812-01 (1)